Polaryx Therapeutics, Inc. (PLYX) Fair Value 2026

PLYX · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 8 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Polaryx Therapeutics, Inc. (PLYX) trades at $2.41, approximately 259% above CirclFi’s Bayesian DCF fair value of $0.67. QOC: 4.3/10. 8/13 models active.

Key Facts

Ticker
PLYX
Price
$2.41
Quality Score
4.3/10
Value Trap Risk
—/100
Models Active
8/13
Last Updated
Strength: First Chicago suggests +110.4% upside with 11% confidence
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

Is Polaryx Therapeutics, Inc. (PLYX) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Polaryx Therapeutics, Inc. (PLYX) appears overvalued as of : the median of 8 independent fair value estimates is $1.52, 37.1% below the current price of $2.41. Estimates range from $0.15 to $5.07. PLYX scores 4.3/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Polaryx Therapeutics, Inc. Stock in 2026? →

Valuation Matrix

8 Intrinsic Value Models vs. Current Price ($2.41)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.67 -72.1%
CUCE Ensemble
Low Conviction
 $1.41 -41.7%
First Chicago
Low Conviction
 $5.07 +110.4%
Dynamic NAV
Medium Conviction
 $0.15 -93.6%

Unlock the Full Matrix

Access 4 additional models including PWERM, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is Polaryx Therapeutics, Inc. (PLYX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Polaryx Therapeutics, Inc. at its current price of $2.41. The composite intrinsic value is estimated at $1.90 (-21.0% average return), with 5 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $5.07 (+110.4%), while Dynamic NAV — the most conservative — estimates $0.15 (-93.6%). This +204.0% gap reflects genuine analytical uncertainty about Polaryx Therapeutics, Inc.'s intrinsic worth.

What Do the Models Say About PLYX?

8 of 13 models are currently active for PLYX. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates PLYX's intrinsic value at $0.67, implying -72.1% downside from the current price. See which stocks rank higher →

How Does PLYX Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, PLYX ranks #299 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Polaryx Therapeutics, Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating PLYX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is PLYX a Value Trap?

The Value Trap algorithm is not active for PLYX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Polaryx Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Polaryx Therapeutics, Inc.'s fundamental quality profile registers 4.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +204.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PLYX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PLYX's 8 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Polaryx Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Polaryx Therapeutics, Inc.

What is Polaryx Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Polaryx Therapeutics, Inc. (PLYX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.67. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PLYX overvalued or undervalued right now?

At $2.41, 2 of 8 active models suggest PLYX may be undervalued, while 6 indicate potential overvaluation. The median of all 8 fair value estimates is $1.52, 37.1% below the current price of $2.41 — a consensus view that PLYX is overvalued. The assessment depends on which methodology best fits Polaryx Therapeutics, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.3 mean for PLYX?

Polaryx Therapeutics, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PLYX?

CirclFi analyzes PLYX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Is PLYX a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for PLYX at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Polaryx Therapeutics, Inc. (PLYX) has a median fair value of $1.52 — 37.1% below the current price of $2.41 — as of 2026-07-15.” Source: circlfi.com/stock/PLYX/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on PLYX.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access